GI
AXSM icon

GAMMA Investing’s Axsome Therapeutics AXSM Stock Holding History

GAMMA Investing’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$76.7K Buy
416
+69
+20% +$15K ﹤0.01% 2072
2026
Q2 		$84.9K Buy
347
+45
+15% +$9.76K ﹤0.01% 1926
2026
Q1 		$51K Buy
302
+34
+13% +$5.87K ﹤0.01% 2162
2025
Q4 		$48.9K Buy
268
+106
+65% +$14.8K ﹤0.01% 2090
2025
Q3 		$19.7K Buy
162
+98
+153% +$11K ﹤0.01% 2523
2025
Q2 		$6.68K Sell
64
-125
-66% -$13.2K ﹤0.01% 3000
2025
Q1 		$22K Buy
189
+132
+232% +$15K ﹤0.01% 2331
2024
Q4 		$4.82K Sell
57
-22
-28% -$2.02K ﹤0.01% 2930
2024
Q3 		$7.1K Buy
79
+42
+114% +$3.67K ﹤0.01% 2597
2024
Q2 		$2.98K Buy
37
+17
+85% +$1.26K ﹤0.01% 2752
2024
Q1 		$1.6K Sell
20
-1
-5% -$84 ﹤0.01% 2815
2023
Q4 		$1.89K Buy
+21
New +$1.4K ﹤0.01% 2593

Other funds holding AXSM

MCP
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return

GAMMA Investing's AXSM Position: Q3 2026 in Review

GAMMA Investing increased its Axsome Therapeutics (AXSM) stake by 20% in Q3 2026, buying an estimated $15K and bringing the position to 416 shares worth $76.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2072.

GAMMA Investing first reported a position in AXSM in Q4 2023 and has held it in 12 quarters since. The position peaked at $84.9K in Q2 2026. 7 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • GAMMA Investing held 416 shares of Axsome Therapeutics worth $76.7K as of Q3 2026.
  • GAMMA Investing bought 69 Axsome Therapeutics shares in Q3 2026, an estimated $15K.
  • Axsome Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2072 holding.
  • GAMMA Investing first reported a position in Axsome Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • GAMMA Investing's Axsome Therapeutics position peaked at $84.9K in Q2 2026.
  • 7 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.